Primary and secondary outcomes according to the NICE DG15 optimal algorithms for (a) the hsTnI assay and (b) the hsTnT assay
| Brisbane | Christchurch | Basel | Combined | |||||
|---|---|---|---|---|---|---|---|---|
| Ruled out | Ruled in | Ruled out | Ruled in | Ruled out | Ruled in | Ruled out | Ruled in | |
| (a) | 695 | 88 | 719 | 246 | 1092 | 288 | 2506 | 622 |
| MI at presentation | 2 (0.3%) | 39 (44.3%) | 12 (1.7%) | 195 (79.3%) | 37 (3.4%) | 193 (67.0%) | 51 (2.0%) | 427 (68.6%) |
| 30-day MACE | 25 (3.6%) | 42 (47.7%) | 86 (12.0%) | 200 (81.3%) | 156 (14.3%) | 215 (74.6%) | 267 (10.7%) | 457 (73.4%) |
| NSTEMI | 2 | 39 | 19 | 195 | 37 | 193 | 58 | 427 |
| UAP | 23 | 3 | 67 | 5 | 119 | 22 | 209 | 30 |
| Brisbane | Christchurch | Basel | Combined | |||||
| Ruled out | Ruled in | Ruled out | Ruled in | Ruled out | Ruled in | Ruled out | Ruled in | |
| (b) | 525 | 275 | 276 | 483 | 993 | 822 | 1794 | 1580 |
| MI at presentation | 2 (0.4%) | 39 (14.1%) | 4 (1.5%) | 163 (33.7%) | 1 (0.1%) | 284 (34.5%) | 7 (0.4%) | 486 (30.8%) |
| 30-day MACE | 21 (4.0%) | 50 (18.2%) | 30 (10.9%) | 200 (41.4%) | 102 (10.3%) | 371 (45.1%) | 153 (8.5%) | 621 (39.3%) |
| NSTEMI | 2 | 42 | 7 | 166 | 1 | 284 | 10 | 492 |
| UAP | 19 | 8 | 23 | 34 | 101 | 87 | 143 | 129 |
DG15, diagnostic guidance 15; MI, myocardial infarction; MACE, major adverse cardiac event; NSTEMI, non-ST elevation myocardial infarction; UAP, unstable angina pectoris; NICE, National Institute for Health and Care Excellence.